Hypercalcemia and idiopathic hypoparathyroidism
Idiopathic primary hypoparathyroidism (prHP) is a rare disorder and clinical experience of its management is limited. Prolonged immobilization of such patients can cause hypercalcemia and hypercalciuria. We report on a boy with prHP who developed hypercalcemia and renal failure as a result of calciu...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 2001-12, Vol.26 (6), p.453-455 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 455 |
|---|---|
| container_issue | 6 |
| container_start_page | 453 |
| container_title | Journal of clinical pharmacy and therapeutics |
| container_volume | 26 |
| creator | Schroth, M. Dötsch, J. Dörr, H. G. |
| description | Idiopathic primary hypoparathyroidism (prHP) is a rare disorder and clinical experience of its management is limited. Prolonged immobilization of such patients can cause hypercalcemia and hypercalciuria. We report on a boy with prHP who developed hypercalcemia and renal failure as a result of calcium and calcitriol substitution not being stopped while he was immobilized for 2 months. Any substitution in patients with prHP must be stopped during prolonged immobilization. Laboratory monitoring is mandatory during this period. |
| doi_str_mv | 10.1046/j.1365-2710.2001.00376.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72301533</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72301533</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4726-c7782926377894c95e21ae87b54590f3d5f897c09c82705d9918ac1685766c933</originalsourceid><addsrcrecordid>eNqNkMlOwzAQQC0EoqXwCyhCgltSL4mXAwdUAQVVgkM5W67jqImyYTei-XscGlGJEyePx2_GMw-AAMEIwZjOiwgRmoSY-QSGEEUQEkaj_QmY_j6cginEVIQxw2wCLpwrIISUYXIOJggxjCknUzBf9q2xWpXaVLkKVJ0GeZo3rdptcx1s-9aH1l962_i8qy7BWaZKZ67GcwY-nh7Xi2W4ent-WTysQu3_o6FmjGOBKfGniLVIDEbKcLZJ4kTAjKRJxgXTUGiOGUxSIRBXGlGeMEq1IGQG7g59W9t8dsbtZJU7bcpS1abpnPR7QJSQAbz5AxZNZ2s_m_RmYkox4R7iB0jbxjlrMtnavFK2lwjKwags5CBODuKGOiR_jMq9L70e-3ebyqTHwlGhB25HQDnvMbOq1rk7cjEU3O_qufsD95WXpv_3APJ18b72EfkGd0mOfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>200466238</pqid></control><display><type>article</type><title>Hypercalcemia and idiopathic hypoparathyroidism</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Schroth, M. ; Dötsch, J. ; Dörr, H. G.</creator><creatorcontrib>Schroth, M. ; Dötsch, J. ; Dörr, H. G.</creatorcontrib><description>Idiopathic primary hypoparathyroidism (prHP) is a rare disorder and clinical experience of its management is limited. Prolonged immobilization of such patients can cause hypercalcemia and hypercalciuria. We report on a boy with prHP who developed hypercalcemia and renal failure as a result of calcium and calcitriol substitution not being stopped while he was immobilized for 2 months. Any substitution in patients with prHP must be stopped during prolonged immobilization. Laboratory monitoring is mandatory during this period.</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1046/j.1365-2710.2001.00376.x</identifier><identifier>PMID: 11722683</identifier><identifier>CODEN: JCPTED</identifier><language>eng</language><publisher>Oxford UK: Blackwell Science Ltd</publisher><subject>Biological and medical sciences ; Calcium - administration & dosage ; Calcium - therapeutic use ; Child ; Drug toxicity and drugs side effects treatment ; Humans ; hypercalcemia ; Hypercalcemia - etiology ; hypercalciuria ; Hypoparathyroidism - complications ; Hypoparathyroidism - therapy ; idiopathic hypoparathyroidism ; immobilization ; Immobilization - adverse effects ; Male ; Medical sciences ; Pharmacology. Drug treatments ; renal failure ; Renal Insufficiency - etiology ; Toxicity: urogenital system</subject><ispartof>Journal of clinical pharmacy and therapeutics, 2001-12, Vol.26 (6), p.453-455</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Dec 2001</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4726-c7782926377894c95e21ae87b54590f3d5f897c09c82705d9918ac1685766c933</citedby><cites>FETCH-LOGICAL-c4726-c7782926377894c95e21ae87b54590f3d5f897c09c82705d9918ac1685766c933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2710.2001.00376.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2710.2001.00376.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14098897$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11722683$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schroth, M.</creatorcontrib><creatorcontrib>Dötsch, J.</creatorcontrib><creatorcontrib>Dörr, H. G.</creatorcontrib><title>Hypercalcemia and idiopathic hypoparathyroidism</title><title>Journal of clinical pharmacy and therapeutics</title><addtitle>J Clin Pharm Ther</addtitle><description>Idiopathic primary hypoparathyroidism (prHP) is a rare disorder and clinical experience of its management is limited. Prolonged immobilization of such patients can cause hypercalcemia and hypercalciuria. We report on a boy with prHP who developed hypercalcemia and renal failure as a result of calcium and calcitriol substitution not being stopped while he was immobilized for 2 months. Any substitution in patients with prHP must be stopped during prolonged immobilization. Laboratory monitoring is mandatory during this period.</description><subject>Biological and medical sciences</subject><subject>Calcium - administration & dosage</subject><subject>Calcium - therapeutic use</subject><subject>Child</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Humans</subject><subject>hypercalcemia</subject><subject>Hypercalcemia - etiology</subject><subject>hypercalciuria</subject><subject>Hypoparathyroidism - complications</subject><subject>Hypoparathyroidism - therapy</subject><subject>idiopathic hypoparathyroidism</subject><subject>immobilization</subject><subject>Immobilization - adverse effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>renal failure</subject><subject>Renal Insufficiency - etiology</subject><subject>Toxicity: urogenital system</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMlOwzAQQC0EoqXwCyhCgltSL4mXAwdUAQVVgkM5W67jqImyYTei-XscGlGJEyePx2_GMw-AAMEIwZjOiwgRmoSY-QSGEEUQEkaj_QmY_j6cginEVIQxw2wCLpwrIISUYXIOJggxjCknUzBf9q2xWpXaVLkKVJ0GeZo3rdptcx1s-9aH1l962_i8qy7BWaZKZ67GcwY-nh7Xi2W4ent-WTysQu3_o6FmjGOBKfGniLVIDEbKcLZJ4kTAjKRJxgXTUGiOGUxSIRBXGlGeMEq1IGQG7g59W9t8dsbtZJU7bcpS1abpnPR7QJSQAbz5AxZNZ2s_m_RmYkox4R7iB0jbxjlrMtnavFK2lwjKwags5CBODuKGOiR_jMq9L70e-3ebyqTHwlGhB25HQDnvMbOq1rk7cjEU3O_qufsD95WXpv_3APJ18b72EfkGd0mOfg</recordid><startdate>200112</startdate><enddate>200112</enddate><creator>Schroth, M.</creator><creator>Dötsch, J.</creator><creator>Dörr, H. G.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Hindawi Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>200112</creationdate><title>Hypercalcemia and idiopathic hypoparathyroidism</title><author>Schroth, M. ; Dötsch, J. ; Dörr, H. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4726-c7782926377894c95e21ae87b54590f3d5f897c09c82705d9918ac1685766c933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Biological and medical sciences</topic><topic>Calcium - administration & dosage</topic><topic>Calcium - therapeutic use</topic><topic>Child</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Humans</topic><topic>hypercalcemia</topic><topic>Hypercalcemia - etiology</topic><topic>hypercalciuria</topic><topic>Hypoparathyroidism - complications</topic><topic>Hypoparathyroidism - therapy</topic><topic>idiopathic hypoparathyroidism</topic><topic>immobilization</topic><topic>Immobilization - adverse effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>renal failure</topic><topic>Renal Insufficiency - etiology</topic><topic>Toxicity: urogenital system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schroth, M.</creatorcontrib><creatorcontrib>Dötsch, J.</creatorcontrib><creatorcontrib>Dörr, H. G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schroth, M.</au><au>Dötsch, J.</au><au>Dörr, H. G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypercalcemia and idiopathic hypoparathyroidism</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><addtitle>J Clin Pharm Ther</addtitle><date>2001-12</date><risdate>2001</risdate><volume>26</volume><issue>6</issue><spage>453</spage><epage>455</epage><pages>453-455</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><coden>JCPTED</coden><abstract>Idiopathic primary hypoparathyroidism (prHP) is a rare disorder and clinical experience of its management is limited. Prolonged immobilization of such patients can cause hypercalcemia and hypercalciuria. We report on a boy with prHP who developed hypercalcemia and renal failure as a result of calcium and calcitriol substitution not being stopped while he was immobilized for 2 months. Any substitution in patients with prHP must be stopped during prolonged immobilization. Laboratory monitoring is mandatory during this period.</abstract><cop>Oxford UK</cop><pub>Blackwell Science Ltd</pub><pmid>11722683</pmid><doi>10.1046/j.1365-2710.2001.00376.x</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-4727 |
| ispartof | Journal of clinical pharmacy and therapeutics, 2001-12, Vol.26 (6), p.453-455 |
| issn | 0269-4727 1365-2710 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72301533 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Biological and medical sciences Calcium - administration & dosage Calcium - therapeutic use Child Drug toxicity and drugs side effects treatment Humans hypercalcemia Hypercalcemia - etiology hypercalciuria Hypoparathyroidism - complications Hypoparathyroidism - therapy idiopathic hypoparathyroidism immobilization Immobilization - adverse effects Male Medical sciences Pharmacology. Drug treatments renal failure Renal Insufficiency - etiology Toxicity: urogenital system |
| title | Hypercalcemia and idiopathic hypoparathyroidism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A41%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypercalcemia%20and%20idiopathic%20hypoparathyroidism&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Schroth,%20M.&rft.date=2001-12&rft.volume=26&rft.issue=6&rft.spage=453&rft.epage=455&rft.pages=453-455&rft.issn=0269-4727&rft.eissn=1365-2710&rft.coden=JCPTED&rft_id=info:doi/10.1046/j.1365-2710.2001.00376.x&rft_dat=%3Cproquest_cross%3E72301533%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=200466238&rft_id=info:pmid/11722683&rfr_iscdi=true |